Literature DB >> 20117056

PML risk and natalizumab: more questions than answers.

Richard M Ransohoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117056     DOI: 10.1016/S1474-4422(10)70025-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

Review 1.  Multiple sclerosis-a quiet revolution.

Authors:  Richard M Ransohoff; David A Hafler; Claudia F Lucchinetti
Journal:  Nat Rev Neurol       Date:  2015-02-17       Impact factor: 42.937

2.  Discrepant findings in immune responses to JC virus in patients receiving natalizumab.

Authors:  Chen S Tan; Yiping Chen; Raphael P Viscidi; R Philip Kinkel; Marion C Stein; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-06       Impact factor: 44.182

3.  [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].

Authors:  C Warnke; O Adams; R Gold; H-P Hartung; R Hohlfeld; H Wiendl; B C Kieseier
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

4.  Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.

Authors:  Fereshteh Ashtari; Mohammad Reza Savoj
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

5.  Postarrest stalling rather than crawling favors CD8(+) over CD4(+) T-cell migration across the blood-brain barrier under flow in vitro.

Authors:  Henriette Rudolph; Armelle Klopstein; Isabelle Gruber; Claudia Blatti; Ruth Lyck; Britta Engelhardt
Journal:  Eur J Immunol       Date:  2016-07-22       Impact factor: 5.532

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.